Whole Body Health Sale

Life Extension Magazine

Life Extension Magazine December 2013
As We See It  

Prostate Cancer Prevention Controversy

By William Faloon

References

  1. Available at: http://www.auanet.org/advnews/press_releases/article.cfm?articleNo=290. Accessed August 22, 2013.
  2. Billis A. Latent carcinoma and atypical lesions of prostate. An autopsy study. Urology. 1986 Oct;28(4):324-9.
  3. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012 Jul 17;157(2):120-34.
  4. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994 May;151(5):1283-90.
  5. Bokhorst LP, Bangma CH, van Leenders GJ, et al. Prostate-specific antigen-based prostate cancer screening: Reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol. Aug 11 2013.
  6. Available at http://www.census.gov/population/age/data/2011comp.html. Accessed September 23,2013.
  7. Available at: http://www.cancer.gov/cancertopics/factsheet/detection/PSA. Accessed September 24, 2013.
  8. Available at: http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Accessed Aug 26, 2013.
  9. Available at: http://www.cdc.gov/hiv/statistics/basics/ataglance.html. Accessed August 27, 2013.
  10. Available at: http://www.uspreventiveservicestaskforce.org/uspstf13/hiv/hivfinalrs.htm. Accessed September 2013.
  11. Ghossain A, Ghossain MA. History of mastectomy before and after Halsted. J Med Liban. 2009 Apr-Jun;57(2):65-71.
  12. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report. 2009 May 5;(13):1-7.
  13. Vessella RL, Lange PH, Partin AW, et al. Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. Urology. 2000 Jun;55(6):909-14.
  14. Lieberman S. Can percent free prostate-specific antigen reduce the need for prostate biopsy? Eff Clin Pract. 1999 Nov-Dec;2(6):266-71.
  15. Stephan C, Stroebel G, Heinau M, et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Cancer. 2005 Sep 1;104(5):993-1003.
  16. Loeb S, Carter HB. Point: Impact of prostate-specific antigen velocity on management decisions and recommendations. J Natl Compr Canc Netw. 2013 Mar 1;11(3):281-5.
  17. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009 May;6(5):255-61.
  18. Strohmeyer D, Frauscher F, Klauser A, et al. Contrast-enhanced transrectal color doppler ultrasonography (TRCDUS) for assessment of angiogenesis in prostate cancer. Anticancer Res. 2001 Jul-Aug;21(4B):2907-13.
  19. Ibrahiem EI, Mohsen T, Nabeeh AM, Osman Y, Hekal IA, Abou El-Ghar M. DWI-MRI: single, informative, and noninvasive technique for prostate cancer diagnosis. ScientificWorldJournal. 2012;2012:973450.
  20. Pollack CE, Platz EA, Bhavsar NA, et al. Primary care providers’ perspectives on discontinuing prostate cancer screening. Cancer. 2012 Nov 15;118(22):5518-24.
  21. Allard CB, Dason S, Lusis J, Kapoor A. Prostate cancer screening: Attitudes and practices of family physicians in Ontario. Can Urol Assoc J. 2012 6(3):188-93.
  22. Qaseem A, Barry MJ, Denberg TD, et al. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013 May 21;158(10):761-9.
  23. Available at: http://www.mikemilken.com/pcfbook_chapter1.pdf. Accessed September 25, 2013.
  24. Available at: http://www.pccnc.org/awareness/. Accessed September 25, 2013.
  25. Post PN, Kil PJ, Hendrikx AJ, Janssen-Heijnen ML, Crommelin MA, Coebergh JW. Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int. 1999 Oct;84(6):652-6.
  26. Howcroft TK, Campisi J, Louis GB, et al. The role of inflammation in age-related disease. Aging (Albany NY). 2013 Jan;5(1):84-93.
  27. Available at: http://www.lef.org/magazine/mag2009/jan2009_Vitamin-K-Protection-Against-Arterial-Calcification-Bone-Loss-Cancer-Aging_01.htm?source=search&key=calcification. Accessed September 25, 2013.
  28. Available at: http://content.onlinejacc.org/article.aspx?articleid=1136110. Accessed September 25, 2013.
  29. Available at: http://circres.ahajournals.org/content/84/2/250.full. Accessed September 25, 2013.
  30. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1161-70.
  31. Available at: http://media.curetoday.com/downloads/documents/BoneHealth_PG_rev_b.pdf. Accessed August 30, 2013.
  32. Beulens JW, Bots ML, Atsma F, et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2009 Apr;203(2):489-93.
  33. Fodor D, Albu A, Poantă L, Porojan M. Vitamin K and vascular calcifications. Acta Physiol Hung. 2010 Sep;97(3):256-66.
  34. Wen J, Zhao Y, Li J, et al. Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells. Prostate. 2013 Jul;73(10):1069-81.
  35. Pezzato E, Sartor L, Dell’Aica I, et al. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-) epigallocatechin-3-gallate. Int J Cancer. 2004 Dec 10;112(5):787-92.
  36. Cox ME, Gleave ME, Zakikhani M, et al. Insulin receptor expression by human prostate cancers. Prostate. 2009 Jan 1;69(1):33-40.
  37. Singh PB, Matanhelia SS, Martin FL. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer. 2008 May;44(7):928-36.
  38. Giton F, de la Taille A, Allory Y, et al. Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa). J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):158-67.
  39. Dagvadorj A, Collins S, Jomain JB, et al. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology. 2007 Jul;148(7):3089-101.
  40. Tu WH, Thomas TZ, Masumori N, et al. The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia. 2003 May-Jun;5(3):267-77.
  41. Ling MT, Lau TC, Zhou C, et al. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). Carcinogenesis. 2005 Oct;26(10):1668-76.
  42. Häggström S, Bergh A, Damber JE. Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma. Prostate. 2000 Sep 15;45(1):42-50.
  43. Meyer F, Galan P, Douville P, et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer. 2005 Aug 20;116(2):182-6.
  44. Ripple MO, Henry WF, Schwarze SR, Wilding G, Weindruch R. Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells. J Natl Cancer Inst. 1999 Jul 21;91(14):1227-32.
  45. Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr. 2009 Apr;89(4):1155-63.
  46. Hussain M, Banerjee M, Sarkar FH, et al. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer. 2003 47(2):111-7.
  47. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 1995 Dec 6;87(23):1767-76.
  48. McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila). 2009 Jul;2(7):673-82.
  49. Liang JY, Liu YY, Zou J, Franklin RB, Costello LC, Feng P. Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate. 1999 Aug 1;40(3):200-7.
  50. Singh RP, Raina K, Sharma G, Agarwal, R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res. 2008 Dec 1;14(23):7773-80.
  51. Smith S, Sepkovic D, Bradlow HL, Auborn KJ. 3,3’-Diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells. J Nutr. 2008 Dec;138(12):2379-85.
  52. Xing N, Chen Y, Mitchell SH, Young CY. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14.
  53. Gupta S, Srivastava M, Ahmad N, et al. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer. 2001 Feb 15;91(4):737-43.
  54. Matsuyama M, Yoshimura R, Mitsuhashi M, et al. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol. 2004 Apr;24(4):821-7.
  55. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun. 1997 Jun 18;235(2):418-23.
  56. Xu S, Gao JP, Zhou WQ. Cyclooxygenase-2 and cyclooxygenase-2 inhibitors in prostate cancer. Zhonghua Nan Ke Xue. 2008 Nov;14(11):1031-4.
  57. Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J Parenter Enteral Nutr. 2006 Jan;30(1):45-51.
  58. Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmermann BN. The effect of turmeric extracts on inflammatory mediator production. Phytomedicine. 2005 Jun;12(6-7):445-52.
  59. Taccone-Gallucci M, Manca-di-Villahermosa S, Battistini L, et al. N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity. Kidney Int. 2006 Apr;69(8):1450-4.
  60. Calder PC. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids. 2003 Apr;38(4):343-52.
  61. Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, Jackson RT. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer. 1999 Dec;81(7):1238-42.
  62. Safayhi H, Sailer ER, Ammon HP. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol. 1995 Jun;47(6):1212-6.
  63. Salinas CA, Kwon EM, FitzGerald LM, et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol. 2010 Sep 1;172(5):578-90.
  64. Bemis DL, Capodice JL, Anastasiadis AG, Katz AE, Buttyan R. Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression. Nutr Cancer. 2005 52(2):202-12.
  65. Yang P, Cartwright C, Chan D, Vijjeswarapu M, Ding J, Newman RA. Zyflamend-mediated inhibition of human prostate cancer PC3 cell proliferation: effects on 12-LOX and Rb protein phosphorylation. Cancer Biol Ther. 2007 6(2):228-36.
  66. Capodice JL, Gorroochurn P, Cammack AS, et al. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial. J Soc Integr Oncol. 2009 7(2):43-51.
  67. Huang EC, McEntee MF, Whelan J. Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer. Nutr Cancer. 2012 64(5):749-60.
  68. Sandur SK, Ahn KS, Ichikawa H, et al. Zyflamend, a polyherbal preparation, inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of NF-kappa B activation and NF-kappa B-regulated gene products. Nutr Cancer. 2007 57(1):78-87.
  69. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009 Apr;17(2):55-67.
  70. Pruthi RS, Derksen JE, Moore D, et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2172-7.
  71. Chen L, Davey Smith G, Evans DM, et al. Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2874-81.
  72. Flanagan JN, Young MV, Persons KS, et al. Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Res. 2006,Jul-Aug;26(4A):2567-72.
  73. Webster J, Piscitelli G, Polli A, et al. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. Clin Endocrinol (Oxf). 1992 Dec;37(6):534-41.
  74. Bohnet HG, Hanker JP, Horowski R, Wickings EJ, Schneider HP. Suppression of prolactin secretion by lisuride throughout the menstrual cycle and in hyperprolactinaemic menstrual disorders. Acta Endocrinol (Copenh). 1979 Sep;92(1):8-19.
  75. Clements A, Gao B, Yeap SH, Wong MK, Ali SS, Gurney H. Metformin in prostate cancer: two for the price of one. Ann Oncol. 2011 Dec;22(12):2556-60.
  76. Hitron A, Adams V, Talbert J, Steinke D. The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol. 2012 Aug;36(4):e243-50.
  77. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control. 2009 Nov;20(9):1617-22.
  78. Teiten MH, Gaascht F, Eifes S, Dicato M, Diederich M. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr. 2010 Mar;5(1):61-74.
  79. Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. Adv Exp Med Biol. 2007 595:127-48.
  80. Reuter S, Gupta SC, Park B, Goel A, Aggarwal BB. Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr. 2011 May;6(2):93-108.
  81. Chen Y, Zaman MS, Deng G, et al. MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res (Phila). 2011 Jan;4(1):76-86.
  82. Lakshman M, Xu L, Ananthanarayanan V, et al. Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res. 2008 Mar 15;68(6):2024-32.
  83. Davis JN, Singh B, Bhuiyan M, Sarkar FH. Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer. 1998 32(3):123-31.
  84. Davis JN, Kucuk O, Sarkar FH. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer. 1999 35(2):167-74.
  85. Berquin IM, Min Y, Wu R, et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest. 2007 Jul;117(7):1866-75.
  86. Deckelbaum RJ, Worgall TS, Seo T. n-3 fatty acids and gene expression. Am J Clin Nutr. 2006 Jun;83(6 Suppl):1520S-1525S.
  87. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem. 2003 Feb 1;88(2):363-71.
  88. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 2000 Aug 4;87(3):214-20.
  89. Yoo J, Lee YJ. Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Mol Pharmacol. 2007 Dec;72(6):1586-92.
  90. Kim KM, Song JJ, An JY, Kwon YT, Lee YJ. Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. J Biol Chem. 2005 Dec 9;280(49):41047-56.
  91. Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010 Sep;46(13):2369-80.
  92. Avci CB, Harman E, Dodurga Y, Susluer SY, Gunduz C. Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev. 2013;14(2):765-8.
  93. Isakovic A, Harhaji L, Stevanovic D, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007 May;64(10):1290-302.
  94. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate. 2003 Oct 1;57(2):134-9.
  95. Schmidt LJ, Regan KM, Anderson SK, Sun Z, Ballman KV, Tindall DJ. Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts. Prostate. 2009 Dec 1;69(16):1730-43.
  96. Available at: http://www.stjohnprovidence.org/InnerPage.aspx?PageID=1446. Accessed September 26, 2013.
  97. Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Rev Urol. 2008 Spring;10(2):111-9.
  98. Gofrit ON, Zorn KC, Taxy JB, etal. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer. J Urol. 2007 Nov;178(5):1925-8.
  99. Bastian PJ, Boorjian SA, Bossi A, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012 Jun;61(6):1096-106.
  100. Carter HB, Partin AW, Walsh PC, et al. Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol. 2012 Dec 10;30(35):4294-6.
  101. Marshall DT, Savage SJ, Garrett-Mayer E, et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012 Jul;97(7):2315-24.
  102. Miano L. Mediterranean diet, micronutrients and prostate carcinoma: a rationale approach to primary prevention of prostate cancer. Arch Ital Urol Androl. 2003 Sep;75(3):166-78.
  103. Itsiopoulos C, Hodge A, Kaimakamis M. Can the Mediterranean diet prevent prostate cancer? Mol Nutr Food Res. 2009 Feb;53(2):227-39.
  104. Ornish D, Magbanua MJ, Weidner G, et al. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8369-74.
  105. Kenfield SA, Chang ST, Chan JM. Diet and lifestyle interventions in active surveillance patients with favorable-risk prostate cancer. Curr Treat Options Oncol. 2007 Jun;8(3):173-96.
  106. Ferris-Tortajada J, Berbel-Tornero O, Garcia-Castell J, Ortega-Garcia JA, Lopez-Andreu JA. Dietetic factors associated with prostate cancer: protective effects of Mediterranean diet. Actas urologicas espanolas. 2012 Apr;36(4):239-245.
  107. Kenfield SA, Dupre N, Richman EL, et al. Mediterranean diet and prostate cancer risk and mortality in the Health Professionals Follow-up Study. Eur Urol. 2013 Aug 13.
  108. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ. 2008 Sep 11;337:a1344.
  109. Xiao D, Srivastava SK, Lew KL, et al. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis. 2003 May;24(5):891-7.
  110. Garikapaty VP, Ashok BT, Chen YG, et al. Anti-carcinogenic and anti-metastatic properties of indole-3-carbinol in prostate cancer. Oncol Rep. 2005 Jan;13(1):89-93.
  111. Srivastava SK, Xiao D, Lew KL, et al. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo. Carcinogenesis. 2003 Oct;24(10):1665-70.
  112. Chuu CP, Chen RY, Kokontis JM, Hiipakka RA, Liao S. Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett. 2009 Mar 8;275(1):86-92.
  113. Thakur VS, Gupta K, Gupta S. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis. 2012 Feb;33(2):377-84.
  114. Punnen S, Hardin J, Cheng I, Klein EA, Witte JS. Impact of meat consumption, preparation, and mutagens on aggressive prostate cancer. PLoS One. 2011 6(11):e27711.
  115. Michaud DS, Augustsson K, Rimm EB, Stampfer MJ, Willet WC, Giovannucci E. A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control. 2001 Aug;12(6):557-67.
  116. Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM. Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival. Cancer Prev Res (Phila). 2011 Dec;4(12):2110-21. 19.
  117. Bidoli E, Talamini R, Bosetti C, et al. Macronutrients, fatty acids, cholesterol and prostate cancer risk. Ann Oncol. 2005 Jan;16(1):152-7.
  118. Freedland SJ, Aronson WJ. Dietary intervention strategies to modulate prostate cancer risk and prognosis. Curr Opin Urol. 2009 May;19(3):263-7.
  119. Song Y, Chavarro JE, Cao Y, et al. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr. 2013 Feb;143(2):189-96.
  120. Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci E. Dairy products, calcium, and prostate cancer risk in the Physicians’ Health Study. Am J Clin Nutr. 2001 74(4):549-554.
  121. Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst. 2005 Dec 7;97(23):1768-77.
  122. Williams CD, Whitley BM, Hoyo C, et al. A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutr Res. 2011 Jan 31(1):1-8.
  123. Masko EM, Allott EH, Freedland SJ. The relationship between nutrition and prostate cancer: is more always better? Eur Urol. 2013 May;63(5):810-20.
  124. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst. 2001 Nov 21;93(22):1687-97.
  125. Available at: http://cdn.intechopen.com/pdfs/24233/InTech-Paradigm_shift_in_the_concept_of_hormonal_milieu_of_prostate_cancer.pdf. Accessed September 30, 2013.
  126. Arena F. Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia. Minerva Urol Nefrol. 2013 Sep;65(3):211-216.
  127. Available at: http://www.medscape.com/viewarticle/745454_4. Accessed September 30, 2013.
  128. Available at: http://www.urologyhealth.org/urology/index.cfm?article=149. Accessed September 30, 2013.
  129. Kristal AR, Till C, Tangen CM, et al. Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride. Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1823-32.
  130. Ta N, Walle T. Aromatase inhibition by bioavailable methylated flavones. J Steroid Biochem Mol Biol. 2007 Oct;107(1-2):127-9.
  131. Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep 19;99(18):1366-74.
  132. Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol. 2004;6 Suppl 9:S31-9.
  133. Yavuz BB, Ozkayar N, Halil M, et al. Free testosterone levels and implications on clinical outcomes in elderly men. Aging Clin Exp Res. 2008 Jun;20(3):201-6
  134. Taira AV, Merrick GS, Galbreath RW, et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis. 2010 Mar;13(1):71-7.
  135. Available at: http://files.shareholder.com/downloads/GHDX/2097290524x0x661617/85f38a0e-ccd5-47de-a348-8d0c2b5c03bd/GHDX_News_2013_5_8_General.pdf. Accessed September 29, 2013.
  136. Available at: http://www.myriad.com/products/prolaris/. Accessed September 29, 2013.
  137. Gharaee-Kermani M, Macoska JA. Promising molecular targets and biomarkers for male BPH and LUTS. Curr Urol Rep. 2013 Aug 3.
  138. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004 May;89(5):2179-84.
  139. Schmidt LJ, Tindall DJ. Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer. J Steroid Biochem Mol Biol. 2011 May;125(1-2):32-8.
  140. Kaplan SA, Ghafar MA, Volpe MA, Lam JS, Fromer D, Te AE. PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study. Urology. 2002 Sep;60(3):464-8.
  141. Handel LN, Agarwal S, Schiff SF, Kelty PJ, Cohen SI. Can effect of finasteride on prostate-specific antigen be used to decrease repeat prostate biopsy? Urology. 2006 Dec;68(6):1220-3.
  142. Available at: http://www.medscape.com/viewarticle/734687. Accessed September 29, 2013.
  143. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul 17;349(3):215-24.
  144. Andriole GL, Bostwick DG, Brawley OW, et al; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 1;362(13):1192-202.
  145. Tan RS, Salazar JA. Risks of testosterone replacement therapy in ageing men. Expert Opin Drug Saf. 2004 Nov;3(6):599-606.
  146. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005 Feb;173(2):533-6.
  147. Gooren L. Androgen deficiency in the aging male: benefits and risks of androgen supplementation. J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):349-55.
  148. Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am. 2007 Nov;34(4):555-63.
  149. Rhoden EL, Averbeck MA, Teloken PE. Androgen replacement in men under-going treatment for prostate cancer. J Sex Med. 2008 Sep;5(9):2202-8.
  150. Raynaud JP. Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):261-6.
  151. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 1998 Apr;159(4):1247-50.
  152. Numao N, Kawakami S, Sakura M, et al. Characteristics and clinical significance of prostate cancers missed by initial transrectal 12-core biopsy. BJU Int. 2012 Mar;109(5):665-71.
  153. Kulkarni GS, Al-Azab R, Lockwood G, et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol. 2006 Feb;175(2):505-9.
  154. Shimamoto T, Ashida S, Yamasaki I, et al. The clinical value of 3 tesla diffusion-weighted magnetic resonance imaging in the diagnosis of prostate cancer. Hinyokika Kiyo. 2012 Mar;58(3):143-8.
  155. Ibrahiem EI, Mohsen T, Nabeeh AM, Osman Y, Hekal IA, Abou El-Ghar M. DWI-MRI: single, informative, and noninvasive technique for prostate cancer diagnosis. Scientific World Journal. 2012 973450.
  156. Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol. 2006 May;175(5):1657-62.
  157. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011 Apr 6;9:33.
  158. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009 Oct 1;69(19):7507-11.
  159. Anisimov VN, Berstein LM, Egormin PA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol. 2005 Aug-Sep;40(8-9):685-93.
  160. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat. 2011 Apr;126(2):355-64.
  161. Tomimoto A, Endo H, Sugiyama M, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 2008 Nov;99(11):2136-41.
  162. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 2008 Aug;110(2):246-50.
  163. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol. 2010 Jan;116(1):92-8.
  164. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009 Sep;32(9):1620-5.
  165. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen—induced lung tumorigenesis. Cancer Prev Res (Phila). 2010 Sep;3(9):1066-76.
  166. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005 Jun 4;330(7503):1304-5
  167. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009 Sep;52(9):1766-77.
  168. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 1993 16(4):621-29.
  169. Choi YK, Park KG. Metabolic roles of AMPK and metformin in cancer cells. Mol Cells. 2013 Jun 19.
  170. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol. 2010 Mar;6(3):457-70.
  171. Ben Sahra I, Regazzetti C, Robert G, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011 Jul 1;71(13):4366-72.
  172. Loubière C, Dirat B, Tanti JF, Bost F. New perspectives for metformin in cancer therapy. Ann Endocrinol (Paris). 2013 May;74(2):130-6.
  173. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila Pa). 2008 Oct;1(5):369-75.
  174. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008 Jun 5;27(25):3576-86.
  175. Ersoy C, Kiyici S, Budak F, et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res Clin Pract. 2008 Jul;81(1):56-60.
  176. Parekh N, Lin Y, Vadiveloo M, Hayes RB, Lu-Yao GL. Metabolic dysregulation of the insulin-glucose axis and risk of obesity-related cancers in the Framingham Heart Study-Offspring Cohort (1971-2008). Cancer Epidemiol Biomarkers Prev. 2013 Sep 24.
  177. Ong KW, Hsu A, Tan BK. Anti-diabetic and anti-lipidemic effects of chlorogenic acid are mediated by ampk activation. Biochem Pharmacol. 2013 May 1;85(9):1341-51.
  178. Dunlap SM, Chiao LJ, Nogueira L, et al. Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prev Res (Phila). 2012 Jul;5(7):930-42.
  179. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01864096. Accessed October 1, 2013.
  180. Available at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=d14acbff-7602-45e9-a577-11db6325068e&cKey=a5dfd7e0-c8eb-4d99-814c-8423fdd9519c&mKey =%7b2D8C569E-B72C-4E7D-AB3B-070BEC7EB280%7d. Accessed October 1, 2013.
  181. Available at: http://journals.lww.com/oncology-times/blog/onlinefirst/pages/post.aspx?Postid=451. Accessed October 10, 2013.
  182. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 2009 Sep;11(3):495-510.
  183. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol. 2013 Apr;63(4):709-16.
  184. Hvid T, Winding K, Rinnov A, et al. Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy. Endocr Relat Cancer. 2013 Aug 19;20(5):621-32.
  185. Available at: http://www.drugs.com/cdi/cabergoline.html. Accessed October 1, 2013.
  186. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. 2011 Oct 11;105(8):1107-13.
  187. St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol. 2006 Oct 15;164(8):760-8.
  188. Egan K, FitzGerald GA. Eicosanoids and the vascular endothelium. Handb Exp Pharmacol. 2006 176 (Pt 1):189-211.
  189. Wu KK. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12.
  190. Available at: http://seer.cancer.gov/faststats/selections.php?run=runit&output=2&data=2&statistic=1&year=201302&race=1 &sex=2&age=1&series=cancer&cancer=66#Output. Accessed October 4, 2013.
  191. Available at: http://www.cancer.gov/cancertopics/factsheet/detection/PSA. Accessed October 4, 2013.
  192. Available at: http://cancerpreventionresearch.aacrjournals.org/content/1/3/174.full. Accessed October 3, 2013.